Probiotics and their metabolite spermidine enhance IFN-γ<sup>+</sup>CD4<sup>+</sup> T cell immunity to inhibit hepatitis B virus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39536754.
- Also identified by DOI 10.1016/j.xcrm.2024.101822 and PMC identifier 11604485.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The therapeutic potential of commensal microbes and their metabolites is promising in the functional cure of chronic hepatitis B virus (HBV) infection, which is defined as hepatitis B surface antigen (HBsAg) loss. Here, using both specific-pathogen-free and germ-free mice, we report that probiotics significantly promote the decline of HBsAg and inhibit HBV replication by enhancing intestinal homeostasis and provoking intrahepatic interferon (IFN)-γ<sup>+</sup>CD4<sup>+</sup> T cell immune response. Depletion of CD4<sup>+</sup> T cells or blockage of IFN-γ abolishes probiotics-mediated HBV inhibition. Specifically, probiotics-derived spermidine accumulates in the gut and transports to the liver, where it exhibits a similar anti-HBV effect. Mechanistically, spermidine enhances IFN-γ<sup>+</sup>CD4<sup>+</sup> T cell immunity by autophagy. Strikingly, administration of probiotics in HBV patients reveals a preliminary trend to accelerate the decline of serum HBsAg. In conclusion, probiotics and their derived spermidine promote HBV clearance via autophagy-enhanced IFN-γ<sup>+</sup>CD4<sup>+</sup> T cell immunity, highlighting the therapeutic potential of probiotics and spermidine for the functional cure of HBV patients.
Medical subject headings
- Probiotics
- Interferon-gamma
- CD4-Positive T-Lymphocytes
- Hepatitis B virus
- Spermidine